Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: A modern hospital medication management setup showing automated dispensing, infusion technology and clinical workflow integration, reflecting BD and Wellstar Health System’s push to improve medication delivery, pharmacy visibility and patient safety through connected hospital systems.
Medical Devices & Diagnostics

Why BD’s Wellstar partnership could reshape medication delivery inside hospitals

Hospitals need safer medication delivery, not more disconnected tech. BD and Wellstar are testing whether AI can close that workflow gap.

Read More
Representative image of a transport-ready ECMO system in a critical care transfer setting, reflecting Medtronic plc’s CE mark approval for the VitalFlow Transport Frame Air and Ground in Europe.
Medical Devices & Diagnostics

Medtronic just cleared a key ECMO transport hurdle, but hospitals still face the harder test

ECMO transport is a clinical weak point. Medtronic’s VitalFlow CE mark tests whether device mobility can strengthen critical care networks.

Read More
Representative image of a robotic-assisted soft tissue surgery setting, highlighting how Johnson & Johnson’s OTTAVA pivotal gastric bypass study could intensify competition in advanced surgical robotics.
Medical Devices & Diagnostics

Johnson & Johnson clears a key OTTAVA hurdle, but the harder robotics test comes next

Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.

Read More
Representative image: A modern radioligand therapy manufacturing centre under construction in Texas, highlighting Novartis AG’s investment in U.S. oncology infrastructure and the growing race to scale precision cancer treatment supply chains.
Medical Devices & Diagnostics

Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology

RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.

Read More
Representative image: Gilead Sciences’ HIV drug growth helped lift its Q1 performance, highlighting how Biktarvy, Descovy and long-acting prevention therapies remain central to the company’s biopharma growth story.
Pharma & Biotech

Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished

Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.

Read More
Representative image: Citius Oncology’s Lymphir commercialisation push highlights the growing pressure on rare cancer biotech firms to turn FDA approvals and fresh funding into real-world treatment adoption.
Pharma & Biotech

Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?

Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.

Read More
Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.
Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More
Representative image: A biotech laboratory scene showing injectable biologic formulation work, reflecting how the Halozyme Therapeutics and Oruka Therapeutics Hypercon agreement could shape the next phase of long-acting psoriasis drug delivery.
Pharma & Biotech

Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody

Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.

Read More
Representative image: Roche’s $1.05bn PathAI acquisition highlights how AI-powered digital pathology could accelerate tissue analysis, companion diagnostics, and precision oncology workflows across modern diagnostics laboratories.
Medical Devices & Diagnostics

What Roche’s $1.05bn PathAI move reveals about the future of pathology labs

Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.

Read More
Representative image of robotic-assisted microsurgery in a modern operating room, illustrating how Microsure’s MUSA-3 CE mark could advance precision surgery, lymphatic procedures, and clinical adoption of specialist surgical robotics in Europe.
Medical Devices & Diagnostics

Can Microsure turn MUSA-3’s CE mark into real hospital adoption in Europe?

Microsure has European clearance for MUSA-3. Now hospitals must decide whether robotic microsurgery can justify adoption.

Read More